Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of Tirzepatide on Gastric Emptying
NCT04407234Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2020
- Primary completion
- Jan 2021
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tirzepatide in obesity and type 2 diabetes mellitus (T2DM), sponsored by Eli Lilly and Company. Primary endpoints: Area Under the Concentration Time Curve From Time Zero to Time T of Acetaminophen at Day 37 and Maximum Observed Drug Concentration of Acetaminophen at Day 37. Started Sep 2020; status: completed.
02
Drugs
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04407234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04407234.